Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review

Introduction: The phase-3 MONALEESA-2, -3 and -7 randomized trials showed benefit of CDK4/6 inhibitor, ribociclib, in women with advanced-stage breast cancer. However, ribociclib-induced acute kidney injury (AKI) was not addressed in these studies. In this report, we explore AKI in breast cancer pat...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Maissoune Hajir, Ramiz Abu-Hijlih, Areej Abu Sheikha, Kholoud Alqasem, Hikmat Abdel-Razeq
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2023-09-01
Ráidu:	Current Problems in Cancer: Case Reports
Fáttát:	Breast cancer Ribociclib Acute kidney injury AKI Endocrine therapy CDK4/6 inhibitors
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2666621923000273
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!